Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial is a research paper published in eClinicalMedicine (2024). On theSindex it has a DataRank of 0.763. It has been cited 31 times, with 27 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.520
From this paper's citation signal
Citation Network Contribution
0.243
From 13 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 27 citers.
Japan Agency for Medical Research and Development
Grant: JP20ck0106622
Japan Agency for Medical Research and Development
Grant: 19EA1008
Japan Agency for Medical Research and Development
Grant: 22ck0106622h0003
FWCI
5.04
Citation Percentile
1.0%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals